Stop Oncology Claim Denials Before They Start
Revenue cycle teams sit at the intersection of the most expensive drugs, the most aggressive prior authorization programs, and the narrowest margins in physician practice. A single denied claim is rarely just a denied claim, it is a regimen mid-cycle, a J-code with 4-5 digits of dollars attached, and a patient already in the chair.
This session walks the denial categories that consistently dominate hematology/oncology AR, mapped to the patient treatment lifecycle they show up in: coverage and eligibility at the start of a regimen, prior authorization mismatch, J-code unit and waste documentation, infusion administration hierarchy, and site-of-service downgrades.
The goal is not denial management as a permanent department function. The goal is fewer denials in the queue next quarter than this one, and the data to prove it.
Tuesday, September 22, 2026